Emergent BioSolutions, Inc. (EBS)
EBS Stock Price Chart
Key Info
| Market Cap | 4.39B |
| Revenue (ttm) | 1.33B |
| Net Income (ttm) | 166.60M |
| Shares Out | 53.00M |
| EPS (ttm) | 3.11 |
| PE Ratio | 26.60 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | December 4 |
| Last Price | $82.80 |
| Previous Close | $82.45 |
| Change ($) | 0.35 |
| Change (%) | 0.42% |
| Day's Open | 82.00 |
| Day's Range | 82.00 - 84.17 |
| Day's Volume | 235,474 |
| 52-Week Range | 49.34 - 134.94 |
EBS Stock News
Investors have been selling these stocks, but patient investors should take advantage of the opportunity.
Could these stocks be winners regardless of which coronavirus vaccine comes out on top?
Is Emergent BioSolutions (EBS) a great pick from the value investor's perspective right now? Read on to know more.
While profitability came in above estimates, the company missed big on the top line.
Emergent (EBS) beats on earnings in Q3 while revenues miss estimates. Total product sales fall year over year and the company tightens its revenue guidance.
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q3 2020 Results - Earnings Call Transcript
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 6.83% and -14.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for ...
On Emergent's (EBS) upcoming third-quarter earnings call, investors will focus on the company's recent CDMO collaborations to help partners manufacture a vaccine against COVID-19.
Emergent Biosolutions (EBS) closed the most recent trading day at $90.77, moving -0.55% from the previous trading session.
Emergent BioSolutions has key niche differentiators that strengthen the operating model, with exposure to defence & public health threats. They hold the only FDA approved anthrax vaccine in th...
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (EBS) Outperforming Other Medical Stocks This Year?
In the latest trading session, Emergent Biosolutions (EBS) closed at $99.55, marking a +1.86% move from the previous day.
Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the f...
Blame it on Johnson & Johnson's pause of a late-stage study of its coronavirus vaccine candidate.
Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.
Forget politics and a pandemic. The outlook for these stocks keeps getting better, and analysts can't keep up.
GAITHERSBURG, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of the Phase 3 clinical trial that will evaluate plasma-derived therap...
Is (EBS) Outperforming Other Medical Stocks This Year?
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
Emergent BioSolutions has been struggling lately, but the selling pressure may be coming to an end soon.
Emergent Biosolutions stock has rallied 111% since late March (vs. about 53% for the S&P 500) to its current level around $105.
Is (EBS) Outperforming Other Medical Stocks This Year?
In case of the S&P 500, whenever the index has gained more than 5% in August, September gains averaged 1.4%.
Strong economic data and positive developments in coronavirus vaccine trials have helped stocks overcome the coronavirus slump. Here are five stocks that can make the most
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?
As of late, it has definitely been a great time to be an investor in Emergent BioSolutions.
GAITHERSBURG, Md., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company’s board of directors appointed Marvin L. White as a Class II direc...
Convalescent plasma holds promise for treating COVID-19, but it's still unproven.
Emergent Biosolutions (EBS) possesses solid growth attributes, which could help it handily outperform the market.
Here we discuss five biotech companies recording impressive growth so far in 2020.
Either company could win the race to develop a COVID-19 vaccine, but one has an easier path to victory.
Emergent's (EBS) Narcan nasal spray gets an FDA nod to extend its shelf life from two years to three years.
GAITHERSBURG, Md., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the fo...
GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the...
GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the...
Emergent BioSolutions CEO on Johnson & Johnson, AstraZeneca vaccine partnerships
Emergent BioSolutions CEO Bob Kramer joined Jim Cramer on "Mad Money" to discuss the biopharmaceutical company's role in the quest to bring a Covid-19 vaccine to market.
Despite a stellar 2.6x rise since the March 23 lows of this year, at the current price of around $130 per share we believe Emergent Biosolutions, best known for its vaccines, antibody therapeu...
GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has completed its previously announced offering of $450 mil...
Top Ranked Momentum Stocks to Buy for August 7th
Emergent BioSolutions: The Indirect COVID-19 Vaccine Play Looks Undervalued
Emergent Biosolutions (EBS) could produce exceptional returns because of its solid growth attributes.
Investors who have the tendency to take a high level of risk can choose momentum stocks.
GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it has priced its offering of $450 million aggregate principal...
GAITHERSBURG, Md., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) (the “Company”) announced today that it intends to offer $400 million aggregate principal amount of...
The IBD SmartSelect Composite Rating for Emergent Biosolutions rose from 94 to 99 Monday. The post Composite Rating For Emergent Biosolutions Rises To 99 appeared first on Investor's Business...
Coronavirus vaccine: Emergent CEO discusses being ready to manufacture coronavirus vaccines
Emergent Biosolutions CEO Bob Kramer joins Yahoo Finance Akiko Fujita to discuss the company's earnings results and his outlook on developing a coronavirus vaccine.
The expert in bioterrorism and emerging infectious diseases had a great second quarter, with more to come.
About EBS
Emergent BioSolutions, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a ty... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Nov 15, 2006 |
| CEO Robert Kramer | Employees 1,834 |
| Stock Exchange NYSE | Ticker Symbol EBS |
Financial Performance
In 2019, EBS's revenue was $1.11 billion, an increase of 41.36% compared to the previous year's $782.40 million. Earnings were $54.50 million, a decrease of -13.08%.
Analyst Forecasts
The average 12-month stock price forecast for EBS is 111.29, which is an increase of 34.41% from the latest price.